As the regulations and expectations of decision makers and stakeholders become more complex, applying the same tools and methodologies will not always suffice. By proactively monitoring the impact of technology trends, we are able to identify and invest in innovative technology-enabled products and services.
Prominent role in industry methods and guidelines development (e.g., ISPOR-SMDM modeling guidelines, ISPOR MCDA emerging good practices, and guidelines for good database selection and use in pharmacoepidemiologic research)
First consortium-developed PRO instrument with qualification statements from both the FDA and EMA in the area of chronic obstructive pulmonary disease (COPD)
Until it was sold in 2018, Evidera developed and operated Evalytica, a cloud-based, software as a service (SaaS) platform providing fast, transparent analysis across heterogeneous real-world data sources, including safety, epidemiology, and health outcomes analytic modules
Developed novel approaches for global value dossiers and payer research (e.g., Rapid Assessment of Payers’ Perspectives on In-licensed Drugs, RAPPID®)
Alternative or add-on to traditional chart review data collection methods utilizing our established and continuously refreshed global network of 2.2 million healthcare providers to provide IRB-approved, rapid real-world evidence that can withstand the rigor of top tier journal peer review
Leading the field in methods for health analytics of novel or atypical data sources (e.g., mining social media for condition mapping/“patient voice,” machine learning for event prediction and predictor discovery)
An efficient way to connect and access clinical sites’ rich EMR data using enhanced health information exchange based technology that enables rapid and streamlined data collection to address a breadth of pertinent research questions
Value story and economic information conveyed directly to the decision maker in a clear, accessible, and high impact format via your tablet, smartphone, or laptop
